{"id":"placebo-chemotherapeutic","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL571546","moleculeType":"Small molecule","molecularWeight":"431.54"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo serves as the inactive comparator arm in phase 3 trials to measure the true therapeutic benefit of the investigational chemotherapeutic drug against no active treatment. The actual mechanism of the active chemotherapeutic agent is not specified in the provided information.","oneSentence":"This is a placebo control used in chemotherapy clinical trials to establish efficacy of an active chemotherapeutic agent.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:51:16.753Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in chemotherapy clinical trial (specific indication unknown)"}]},"trialDetails":[{"nctId":"NCT07049055","phase":"PHASE1, PHASE2","title":"A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer","status":"RECRUITING","sponsor":"Engeneic Pty Limited","startDate":"2026-01-12","conditions":"Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":144},{"nctId":"NCT06570811","phase":"PHASE2","title":"Coenzyme Q10 and Chemotherapeutic Toxicity in Breast Cancer Patients","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2024-08-01","conditions":"Breast Cancer, Chemotherapeutic Toxicity","enrollment":40},{"nctId":"NCT04246177","phase":"PHASE3","title":"Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-05-22","conditions":"Carcinoma, Hepatocellular","enrollment":480},{"nctId":"NCT05403385","phase":"PHASE2","title":"Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"iTeos Therapeutics","startDate":"2022-08-26","conditions":"Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer","enrollment":36},{"nctId":"NCT04615884","phase":"NA","title":"Use of Chinese Herbal Formula Shu Yu Wan in Lung Cancer Patients","status":"WITHDRAWN","sponsor":"Lady Davis Institute","startDate":"2022-03","conditions":"Metastatic NSCLC","enrollment":""},{"nctId":"NCT05137067","phase":"PHASE2","title":"A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.","status":"COMPLETED","sponsor":"Optimal Health Research","startDate":"2021-01-20","conditions":"Breast Cancer, Lung Cancer, Prostate Cancer","enrollment":90},{"nctId":"NCT02897700","phase":"PHASE1","title":"A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2013-01","conditions":"Breast Cancer","enrollment":300},{"nctId":"NCT05435742","phase":"PHASE1, PHASE2","title":"SON-080 in Patients With Persistent Chemotherapy-induced Peripheral Neuropathy (CIPN)","status":"TERMINATED","sponsor":"Sonnet BioTherapeutics","startDate":"2022-10-27","conditions":"Chemotherapy-induced Peripheral Neuropathy (CIPN)","enrollment":9},{"nctId":"NCT02586025","phase":"PHASE3","title":"Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-03-14","conditions":"Breast Cancer","enrollment":329},{"nctId":"NCT01099449","phase":"PHASE3","title":"Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2010-06","conditions":"Chemotherapeutic Agent Toxicity, Colorectal Cancer, Neuropathy","enrollment":362},{"nctId":"NCT00602030","phase":"PHASE1, PHASE2","title":"Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC","status":"COMPLETED","sponsor":"Syndax Pharmaceuticals","startDate":"2008-01-08","conditions":"Non-Small-Cell Lung Carcinoma, Carcinoma, Non-Small Cell Lung","enrollment":141},{"nctId":"NCT05230654","phase":"NA","title":"Efficacy and Safety of Fosaprepitant in Preventing Chemotherapy-induced Vomiting in Children Treated With Medium and High Emetic Chemotherapeutic Drugs","status":"UNKNOWN","sponsor":"Shanghai Children's Medical Center","startDate":"2022-02-01","conditions":"Chemotherapy Induced Nausea and Vomiting Pediatric Cancer Patients","enrollment":120},{"nctId":"NCT04232423","phase":"PHASE3","title":"Olanzapine for Chemotherapy-induced Nausea and Vomiting Prophylaxis","status":"COMPLETED","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2020-03-01","conditions":"Complete Response Rate to Chemotherapy-induced Nausea and Vomiting Prophylaxis","enrollment":90},{"nctId":"NCT04781725","phase":"PHASE2","title":"INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer","status":"UNKNOWN","sponsor":"Ottawa Hospital Research Institute","startDate":"2021-03-25","conditions":"Breast Cancer","enrollment":90},{"nctId":"NCT04316364","phase":"PHASE3","title":"A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-07-14","conditions":"Non-Small-Cell Lung Cancer","enrollment":537},{"nctId":"NCT05092113","phase":"PHASE3","title":"The Efficacy and Safety of a Compound Glutamine Capsule in the Primary Prevention of Chemotherapy-induced Mucositis","status":"UNKNOWN","sponsor":"Meng Qiu","startDate":"2021-06-30","conditions":"Mucositis, Chemotherapeutic Toxicity","enrollment":108},{"nctId":"NCT04607642","phase":"PHASE2","title":"Trial of BMX-001 or Placebo in Head and Neck Cancer Patients","status":"WITHDRAWN","sponsor":"BioMimetix JV, LLC","startDate":"2021-07","conditions":"Head and Neck Cancer","enrollment":""},{"nctId":"NCT04651608","phase":"NA","title":"The Effect of Acupressure Chemotherapy-related Nausea Vomiting in Children","status":"COMPLETED","sponsor":"Akdeniz University","startDate":"2017-03-01","conditions":"Pediatric Cancer, Nausea With Vomiting Chemotherapy-Induced","enrollment":44},{"nctId":"NCT00748215","phase":"PHASE2","title":"Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-02-04","conditions":"Chemotherapeutic Agent Toxicity, Colorectal Cancer, Diarrhea","enrollment":100},{"nctId":"NCT04435028","phase":"","title":"Ketotifen: as a Cardioprotective Agent in Breast Cancer Patients Receiving Anthracycline-containing Chemotherapy","status":"COMPLETED","sponsor":"Horus University","startDate":"2019-01-14","conditions":"Breast Cancer, Iron Chelation","enrollment":111},{"nctId":"NCT04113096","phase":"EARLY_PHASE1","title":"Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer","status":"UNKNOWN","sponsor":"The University of The West Indies","startDate":"2018-10-01","conditions":"Stage IV Prostate Cancer, Stage IV Colon Cancer, Stage IV Breast Cancer","enrollment":104},{"nctId":"NCT01362530","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-09-13","conditions":"Chemotherapy Induced Nausea and Vomiting","enrollment":307},{"nctId":"NCT02706184","phase":"PHASE3","title":"E. Coli Nissle in Oncology","status":"COMPLETED","sponsor":"University of Hohenheim","startDate":"2015-07","conditions":"Gastric Cancer, Colorectal Cancer","enrollment":20},{"nctId":"NCT00754767","phase":"PHASE4","title":"L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer","status":"TERMINATED","sponsor":"HealthPartners Institute","startDate":"2007-01-02","conditions":"Breast Cancer, Chemotherapeutic Agent Toxicity, Neurotoxicity","enrollment":2},{"nctId":"NCT00775645","phase":"PHASE3","title":"S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2009-09","conditions":"Breast Cancer, Chemotherapeutic Agent Toxicity, Fatigue","enrollment":437},{"nctId":"NCT01697072","phase":"PHASE3","title":"First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma","status":"TERMINATED","sponsor":"Amgen","startDate":"2012-10","conditions":"Gastric Cancer","enrollment":609},{"nctId":"NCT00486213","phase":"PHASE3","title":"Pyridoxine in Preventing Hand-Foot Syndrome Caused by Capecitabine in Patients With Cancer","status":"TERMINATED","sponsor":"National Cancer Centre, Singapore","startDate":"2007-06","conditions":"Dermatologic Complications, Palmar-plantar Erythrodysesthesia, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":210},{"nctId":"NCT00333229","phase":"PHASE4","title":"A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-03","conditions":"Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women","enrollment":11},{"nctId":"NCT01214720","phase":"PHASE3","title":"A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-07","conditions":"Pancreatic Cancer","enrollment":607},{"nctId":"NCT00394966","phase":"PHASE2","title":"A Multicenter, Randomized, Controlled Trial of SCH 619734 for the Treatment of Chemotherapy-Induced Nausea and Vomiting (Study P04351AM2)(COMPLETED)","status":"COMPLETED","sponsor":"Schering-Plough","startDate":"2006-09","conditions":"Nausea, Vomiting","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo、Chemotherapeutic","genericName":"Placebo、Chemotherapeutic","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo control used in chemotherapy clinical trials to establish efficacy of an active chemotherapeutic agent. Used for Control arm in chemotherapy clinical trial (specific indication unknown).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}